Flow Cytometers and Related Reagents
Total Trials
24
As Lead Sponsor
11
As Collaborator
13
Total Enrollment
50,618
NCT01451086
Safety and Immunogenicity of 23-valent Pneumococcal Polysaccharide Vaccine in 2 to 70 Years Old Healthy People in China
Phase: Phase 3
Role: Collaborator
Start: Oct 31, 2011
Completion: Aug 31, 2012
NCT02003495
Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine
Role: Lead Sponsor
Start: Oct 31, 2013
Completion: Oct 31, 2014
NCT02003313
Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine
Start: Nov 30, 2013
Completion: Jul 31, 2015
NCT02560272
Safety and Immunogenicity of Haemophilus Influenzae Type b Conjugate Vaccine，Freeze-dried
Start: Sep 30, 2014
Completion: Jun 30, 2016
NCT02281396
The Safety Research of Freeze-dried Rabies Vaccine（MRC-5 Cell) in Chinese Humans
Phase: Phase 1
Start: Nov 30, 2014
Completion: May 31, 2015
NCT02288286
Safety and Immunogenicity of Freeze-dried Rabies Vaccine（MRC-5 Cell) in Chinese Humans
Completion: Apr 30, 2015
NCT02494999
A Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants
Start: Jun 30, 2016
Completion: Oct 31, 2019
NCT04264598
Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine
Start: Aug 21, 2017
Completion: Dec 28, 2018
NCT03902054
Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine.
Phase: Phase 2
Start: Dec 28, 2017
NCT06210737
A Study to Evaluate Persistence of Immunity of PCV13 in Healthy Population Aged 2 Months，7 Months-5 Years
Phase: Phase 4
Start: Sep 26, 2019
Completion: Nov 13, 2022
NCT04758273
A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)
Start: Oct 7, 2020
Completion: Feb 28, 2022
NCT04756323
A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)
Start: Oct 27, 2020
NCT04852705
A Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Adults Aged 18 Years and Older (COVID-19)
Start: May 31, 2021
Completion: Nov 30, 2022
NCT04943718
Personalized Vaccine for Patients With Recurrent Malignant Glioma
Start: Jul 15, 2021
Completion: Jun 13, 2024
NCT05003479
Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years(COVID-19)
Start: Aug 31, 2021
Completion: Oct 31, 2022
NCT05003466
Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 3 to 17 Years(COVID-19)
Start: Sep 30, 2021
Completion: Apr 30, 2023
NCT05290415
Host DNA Methylation for Endometrial Cancer Screening
Phase: N/A
Start: Mar 13, 2022
Completion: Sep 13, 2022
NCT06284226
An Exploratory Clinical Study to Evaluate the Safety and Efficacy of NK Cells (Combined With Standard Therapy) in the Treatment of Solid Tumor Patients
Phase: Early Phase 1
Start: Mar 25, 2022
Completion: Dec 31, 2025
NCT06752174
A Study to Evaluate Safety and Immunogenicity of Sequential Vaccination of Sabin Inactivated Poliomyelitis Vaccine (Vero Cell) and Live Attenuated Poliomyelitis Vaccine in Healthy 2-month-old Infants
Start: Mar 8, 2023
Completion: Apr 12, 2024
NCT05750017
A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine
Start: Mar 23, 2023
Completion: Mar 15, 2024
NCT05760703
Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B
Start: Apr 25, 2023
Completion: Dec 11, 2023
NCT05760781
To Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B
NCT06088745
A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine
Start: Sep 28, 2023
Completion: Dec 31, 2026
NCT06608199
A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 Vaccine
Start: Nov 1, 2024
Completion: Oct 1, 2026
Loading map...